A recent scientific assessment by the European Food Safety Authority (EFSA) has raised questions about the health claims surrounding the polyphenolic apple extract powder, Appl’In®, which is derived from the Malus domestica apple. The panel on Dietetic Products, Nutrition and Allergies undertook a thorough review of the evidence provided by Diana Naturals, which sought to substantiate claims that this apple extract could significantly reduce post-prandial glycaemic responses—a critical factor for managing blood sugar levels after meals.
The panel’s findings indicate that while Appl’In® contains at least 5% phloridzin, a compound often associated with beneficial health effects, the evidence supporting its effectiveness in reducing blood sugar spikes is lacking. Lead author from the EFSA panel noted, “The studies provided did not sufficiently demonstrate a cause and effect relationship between the consumption of Appl’In® and the claimed health benefits.” This conclusion is particularly significant for consumers and manufacturers alike, as it casts doubt on the marketing strategies that may have been built around these health claims.
Diana Naturals submitted a combination of human, animal, and in vitro studies to back their assertions. However, the EFSA panel highlighted that one of the human studies did not comply with the necessary specifications, rendering it ineffective for substantiating the claim. Furthermore, the other studies measured post-prandial blood glucose levels but did not assess insulin responses, which are crucial for a complete understanding of glycaemic control. The panel stated, “No conclusions can be drawn from these studies for the scientific substantiation of the claim,” emphasizing the need for robust, compliant research before health claims can be validated.
The implications of this assessment extend beyond the realm of dietary supplements and health foods; they touch upon broader commercial interests in the energy sector. As consumers increasingly seek products that promise health benefits, companies in the energy and nutrition markets must navigate these regulatory landscapes carefully. The failure to substantiate health claims may lead to reduced consumer trust and impact sales for products marketed under similar pretenses.
This development underscores the importance of rigorous scientific validation in the booming market for functional foods and supplements. Companies may need to invest more in research and development to ensure their products meet regulatory standards and truly deliver on health promises. As the EFSA panel’s findings are published in the EFSA Journal, or the European Food Safety Authority Journal, stakeholders across the industry will be watching closely to see how this may influence product formulation and marketing strategies in the future.
For more information on the EFSA panel’s work, you can visit their official page at EFSA.
